Abstracts tagged "stem cells and systemic sclerosis"

Abstract Number: 899 • 2018 ACR/ARHP Annual Meeting
Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates
Shervin Assassi¹, Xuan Wang², Jun Ying³, Lynette Keyes-Elstein⁴, Ellen Goldmuntz⁵, Jacob Turner⁶, Wenjin Zheng⁷, Guocai Chen⁷, Maria Virginia Pascual⁸, John Varga⁹, Monique Hinchcliff¹⁰, Chiara Bellocchi¹¹, Peter McSweeney¹², Daniel E. Furst¹³, Richard Nash¹², Leslie Crofford¹⁴, Beverly Welch¹⁵, Ashley Pinckney¹⁶, Maureen D. Mayes¹ and Keith Sullivan¹⁷, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Baylor Scott & White Health, Dallas, TX, ³Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴Rho, Inc, Chapel Hill, NC, ⁵NIAID, National Institutes of Health, Bethesda, MD, ⁶Stephen F Austin University, Nacogdoches, TX, ⁷University of Texas Health Science Center at Houston, Houston, TX, ⁸Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY, ⁹Northwestern University, Chicago, IL, ¹⁰Rheumatology, Northwestern University, Chicago, IL, ¹¹Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹²Colorado Blood Cancer Institute, Denver, CO, ¹³University of California Los Angeles, Los Angeles, CA, ¹⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁵National Institutes of Health, Bethesda, MD, ¹⁶Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁷Duke University Medical Center, Durham, NC
Background/Purpose: Myeloablation followed by autologous hematopoietic stem cell transplantation (HSCT) led to improved clinical outcomes compared to 12 monthly infusions of cyclophosphamide (CYC) in patients…
Abstract Number: 1688 • 2017 ACR/ARHP Annual Meeting
Stem Cell-Enriched Lipotransfer Substantially Improves Measures of Appearance and Function Due to Facial Fibrosis in Systemic Sclerosis
Aurora Almadori^1,2, Caroline Ryan², Michelle Griffin³, Esther Hansen⁴, Christopher Denton⁵ and Peter Butler^6,7, ¹Plastic Surgery, Royal Free NHS Foundation Trust London Hospital, London, United Kingdom, ²Division of Surgery and Interventional Science, UCL, London, United Kingdom, ³Division of Surgery and Interventional Sclemce, UCL, london, United Kingdom, ⁴Clinical Psychology, Plastic Surgery, Royal Free London NHS Foundation Trust Hospital, London, United Kingdom, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁶Plastic Surgery, Royal Free London NHS Foundation Trust Hospital, London, United Kingdom, ⁷Division of Surgery and Interveitional Science, UCL, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is characterised by fibrosis of the skin and underlying connective tissue structures, together with localised loss of subcutaneous fat. Oro-facial fibrosis…
Abstract Number: 1858 • 2016 ACR/ARHP Annual Meeting
Phenotypical and Functional Characteristics of in Vitro Expanded Adipose-Derived Mesenchymal Stem Cells from Patients with Systemic Sclerosis
Nicoletta Del Papa¹, Chiara Capelli², Eleonora Zaccara¹, Paola Cipriani³, Paola Di Benedetto⁴, Wanda Maglione¹, Romina Andracco¹, Francesca Pignataro¹, Roberto Giacomelli⁴, Martino Introna⁵ and Claudio Vitali⁶, ¹Dept. Rheumatology, G. Pini Hospital, Milano, Italy, ²Laboratorio di Terapia Cellulare e Genica "G. Lanzani",, Ospedali Riuniti di Bergamo, Bergamo, Italy, ³Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L’Aquila, L'Aquila, Italy, ⁴Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L’Aquila, L’Aquila, Italy, ⁵Laboratorio di Terapia Cellulare e Genica "G. Lanzani", Ospedali Riuniti di Bergamo, Bergamo, Italy, ⁶Rheumatology Section, Istituto San Giuseppe, Como, Italy
Background/Purpose: Adult stem cells, namely those of mesenchymal origin (MSCs), have received attention as an ideal source of regenerative cells because of their multi-potential ability…
Abstract Number: 879 • 2014 ACR/ARHP Annual Meeting
Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up
Eleonora Zaccara¹, Domenico Sambataro², Wanda Maglione¹, Gianluca Sambataro¹, Francesco Onida³, Claudio Annaloro³, Giorgia Saporiti³, Elena Tagliaferri³, Agostino Cortelezzi³, Rosaria Giordano⁴, Claudio Vitali⁵ and Nicoletta Del Papa², ¹U.O.C. Day Hospital Reumatologia, Osp. G. Pini, Milano, Italy, ²Rheumatology Unit, Istituto G.Pini, Milan, Italy, ³Hematology-BMT Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, ⁴Franco Calori Cell Factory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, ⁵Sezione Reumatologia, Istituto San Giuseppe, Lecco, Italy
Background/Purpose In the recent years, autologous haematopoietic stem cell transplantation (AHSCT) has been shown to represent an effective therapeutic option for patients (pts) suffering from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].